Clostridium difficile infection – European Clinical Trials Information Network

A study to evaluate the effectiveness of AZD5148 in preventing the recurrence of Clostridioides difficile infection in adults.

Wed, 29 Apr 2026 15:09:05 +0000

This study investigates a way to prevent the return of Clostridioides difficile infection, a type of infection in the gut that often causes severe diarrhea. The research aims to determine if a new medication can reduce how often the infection comes back after the initial treatment. The medication being tested is called AZD5148, which is a monoclonal antibody. A monoclonal antibody is a type of protein made in a laboratory that is designed to find and attach to specific targets in the body, such as the toxin B produced by the bacteria.

Participants in the study will receive either AZD5148 or a placebo. The medication will be given as an intravenous infusion, which means it is delivered directly into a vein through a needle or tube. This treatment is administered alongside standard care, which includes regular antibacterial drugs used to treat the current infection. During the study, individuals will be monitored to see if the infection returns within a specific period of time.

Study on Optimizing Antibiotic Treatment for Clostridioides Difficile Infection with Vancomycin Hydrochloride in Adult Patients

Wed, 29 Apr 2026 15:03:37 +0000

This clinical trial is focused on studying the treatment of Clostridioides difficile infection, commonly known as C. difficile or CDI. This infection can cause severe diarrhea and other intestinal issues. The study will use a medication called vancomycin hydrochloride, which is taken orally in the form of hard capsules. The purpose of the study is to determine if a shorter, 5-day treatment with vancomycin is as effective as the standard 10-day treatment.

Participants in the study will be randomly assigned to receive either the 5-day or the 10-day course of vancomycin. Throughout the study, the health of participants will be monitored to assess the recurrence of CDI and overall recovery. Recovery is defined as a noticeable improvement in symptoms, such as reduced stool frequency and a return to normal stool consistency, without the appearance of new severe symptoms.

The study will also collect additional information, such as the presence of multidrug-resistant bacteria and changes in the gut microbiota, which are the microorganisms living in the intestines. This information will help researchers understand the broader effects of the treatment. The study is expected to continue until the end of 2027.

Study on VE303 for Preventing Recurrent C. difficile Infection in Patients

Wed, 29 Apr 2026 14:58:33 +0000

This clinical trial is focused on studying a condition known as Clostridioides difficile infection, often referred to as CDI. This infection can cause severe diarrhea and other intestinal issues. The study is testing a new treatment called VE303, which is a capsule containing live bacteria that are believed to help restore balance in the gut. The trial will compare the effects of VE303 with a placebo, which looks like the VE303 capsule but does not contain any active bacteria.

The purpose of the study is to see if VE303 can prevent the recurrence of CDI. Participants in the study will be randomly assigned to receive either VE303 or the placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. The treatment will be taken orally, and the study will last for several weeks, with follow-up checks to monitor the participants’ health and any recurrence of the infection.

Throughout the study, participants will be asked to attend regular visits, provide samples, and complete questionnaires to help researchers gather data on the effectiveness of VE303. The main goal is to determine if VE303 can reduce the rate of CDI recurrence by the end of the study period. Participants’ health and any side effects will be closely monitored to ensure safety and gather comprehensive results.

Study on Preventing C. difficile Infections with Oral Vancomycin in Patients Undergoing Allogeneic Stem Cell Transplantation

Wed, 29 Apr 2026 14:27:59 +0000

This clinical trial is focused on preventing Clostridium difficile infections in patients who are undergoing a medical procedure called allogeneic hematopoietic stem cell transplantation. This procedure involves replacing a patient’s blood-forming cells with those from a donor. The study will use a medication called vancomycin, which is an antibiotic, to see if it can help prevent these infections. Some patients will receive vancomycin, while others will receive a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to evaluate if taking oral vancomycin can effectively prevent Clostridium difficile infections in these patients. Participants in the study will be randomly assigned to receive either vancomycin or a placebo. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased.

Throughout the study, participants will be monitored for signs of Clostridium difficile infection, which can cause symptoms like diarrhea. The study will last for several weeks, and participants will be observed from the time they are included in the study until they are discharged from the hospital or until the end of the treatment period. The study aims to provide valuable information on whether vancomycin can be a useful preventive treatment for these infections in patients undergoing this type of transplantation.

Study on EXL01 to Prevent Recurrence of C. difficile Infection in High-Risk Patients

Wed, 29 Apr 2026 14:26:03 +0000

This clinical trial is focused on studying a condition known as Clostridioides difficile infection, often referred to as C. difficile or CDI. This infection can cause severe diarrhea and other intestinal issues, and it is known for recurring in some patients. The study is particularly interested in patients who have experienced multiple recurrences of this infection. The treatment being tested is a new product called EXL01, which is a type of live biotherapeutic product. This means it contains live microorganisms that are intended to help restore the natural balance of bacteria in the gut. The study will also involve the use of Vancomycin, a medication commonly used to treat C. difficile infections.

The purpose of the study is to evaluate the safety and effectiveness of EXL01 in preventing the recurrence of C. difficile infection in patients who are at high risk of experiencing another episode. The study will be conducted in two phases. In the first phase, the focus will be on assessing how safe and tolerable EXL01 is for patients. In the second phase, the study will look at how well EXL01 works in preventing the infection from coming back. Participants will receive the treatment and be monitored over a period of time to see if the infection recurs and to check for any side effects.

Throughout the study, participants will be asked to take EXL01 in the form of a hard capsule, and they will continue their treatment with Vancomycin as prescribed. The study will involve regular check-ups to monitor the participants’ health, the number of bowel movements, and the consistency of stools. The overall goal is to determine if EXL01 can effectively prevent future episodes of C. difficile infection, thereby improving the quality of life for those affected by this condition.